<DOC>
	<DOCNO>NCT00003712</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness CCI-779 treating patient advance solid tumor .</brief_summary>
	<brief_title>CCI-779 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety , tolerability , maximum tolerate dose ( MTD ) CCI-779 patient advance solid tumor ( part I ) receive anticonvulsant therapy . - Determine safety , tolerability , MTD patient recurrent gliomas brain metastasis ( part II ) receive anticonvulsant therapy . - Determine preliminary pharmacokinetic profile antitumor activity CCI-779 patient . OUTLINE : This open-label , dose-escalation study . - Part I : Patients receive CCI-779 IV 30 minute day 1-5 , follow 9 day rest period . Treatment course repeat every 2 week absence disease progression unacceptable toxicity . The maximum tolerate dose part I define dose level 33 % patient experience dose limit toxicity . - Part II : Patients receive treatment schedule part I . Three patient CNS tumor enter dose CCI-779 determine MTD Part I . At least 3 patient enter dose level part II . PROJECTED ACCRUAL : Approximately 20 patient accrued part I study within 8 month , 12 patient accrue part II within 7 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Part I : Histologically proven advanced solid tumor refractory curative therapy exist No CNS metastasis , peritumoral edema , symptomatic brain metastasis ( part I ) Measurable evaluable disease Part II : Histologically proven recurrent glioma brain metastasis curative therapy exist Receiving anticonvulsant Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 1.5 mg/dL AST ALT less 3 time upper limit normal ( ULN ) ( less 5 time ULN liver metastasis ) Renal : Creatinine le 2 mg/dL Cardiovascular : No unstable angina No myocardial infarction within past 6 month No maintenance therapy lifethreatening arrhythmias Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No active infection serious concurrent illness Triglycerides great 300 mg/dL Cholesterol great 350 mg/dL No known hypersensitivity macrolide antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week since nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid use reduce edema patient primary metastatic CNS tumor allow No concurrent hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : At least 1 month since prior investigational agent At least 3 week since prior immunosuppressive therapy No concurrent anticonvulsant therapy ( part I ) No concurrent immunosuppressive therapy ( e.g. , terfenadine , cisapride , astemizole , pimozide ) No known agent inhibit induce cytochrome p450</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>